[go: up one dir, main page]

Geisslinger et al., 1990 - Google Patents

Pharmacokinetics of S (+)-and R (−)-ibuprofen in volunteers and first clinical experience of S (+)-ibuprofen in rheumatoid arthritis

Geisslinger et al., 1990

Document ID
17817327849728407186
Author
Geisslinger G
Schuster O
Stock K
Loew D
Bach G
Brune K
Publication year
Publication venue
European journal of clinical pharmacology

External Links

Snippet

Summary S (+)-, R (−)-or racemic ibuprofen was administered orally to volunteers in doses of 150 mg, 300 mg and 500 mg pure S (+)-, 300 mg pure R (−)-and 600 mg racemic ibuprofen. The pharmacokinetic parameters in humans showed that S (+)-ibuprofen was not …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Geisslinger et al. Pharmacokinetics of S (+)-and R (−)-ibuprofen in volunteers and first clinical experience of S (+)-ibuprofen in rheumatoid arthritis
Bannwarth et al. Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol.
Borgström et al. Pharmacokinetics of N-acetylcysteine in man
RU2140266C1 (en) Sustained-release pharmaceutical composition based on one or some pharmaceutically acceptable gamma-hydroxybutyric acid salts, method of its preparing
Perucca et al. Disposition of sodium valproate in epileptic patients.
Hansen et al. Sulthiame (Ospolot®) as inhibitor of diphenylhydantoin metabolism
Geisslinger et al. Pharmacological differences between R (−)-and S (+)-ibuprofen
Kates Calcium antagonists: pharmacokinetic properties
Rivera‐Calimlim et al. Absorption and metabolism of L‐dopa by the human stomach
Jamali et al. Pharmacokinetics of ibuprofen enantiomers in humans following oral administration of tablets with different absorption rates
Kreek et al. Stereoselective disposition of methadone in man
Rey et al. Pharmacokinetics of the individual enantiomers of vigabatrin (gamma‐vinyl GABA) in epileptic children.
ZIANCE et al. A comparison of the effects of fenfluramine and amphetamine on uptake, release and catabolism of norepinephrine in rat brain
JP2013056918A (en) Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
Nagy et al. Plasma levels of imipramine and desipramine in man after different routes of administration
Wilson et al. Death in an adolescent following an overdose of acetaminophen and phenobarbital
Knott et al. Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy.
Westenberg et al. Kinetics of l-5-hydroxytryptophan in healthy subjects
Goldberg et al. Lack of effect of oral activated charcoal on imipramine clearance
Crook et al. The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease
Bach et al. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
Krämer et al. Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique
Davis Antimalarial drugs and glucose metabolism
Troupin et al. Felbamate: therapeutic range and other kinetic information
Wolen et al. The effect of crystal size on the bioavailability of benoxaprofen: studies utilizing deuterium labeled drug